SKIC2抗体;SKIC2 Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: 293T, K562, Jurkat and 231 cell, Primary antibody: P08938(UCHL3 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08938(UCHL3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08938(UCHL3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The SKIC2 antibody is a monoclonal antibody primarily used in research and diagnostic applications to detect specific protein targets associated with cellular processes, particularly in cancer biology. It was developed to recognize epitopes on antigens involved in signaling pathways, tumor progression, or immune regulation. While the exact target of SKIC2 may vary depending on the study context, it has been referenced in investigations related to ovarian cancer biomarkers, such as the HE4 (Human Epididymis Protein 4), where it aids in distinguishing malignant from benign conditions.

Structurally, SKIC2 is typically an IgG-class antibody produced in murine or other mammalian host systems. Its high specificity and affinity make it suitable for techniques like immunohistochemistry (IHC), ELISA, and Western blotting. Researchers utilize SKIC2 to explore protein expression patterns in tissues or serum samples, contributing to biomarker validation and therapeutic target identification. Commercial variants often include validation data for reproducibility across experimental models. Despite its niche application, SKIC2 remains a tool for understanding tumor microenvironments and improving diagnostic accuracy in oncology. Further studies aim to refine its utility in clinical settings.